salarius is an oncology based biotechnology company developing targeted treatments for patients who need them the most.
Company profile
Ticker
SLRX
Exchange
Website
CEO
David Arthur
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Flex Pharma, Inc.
SEC CIK
SLRX stock data
Latest filings (excl ownership)
10-K/A
2023 FY
Annual report (amended)
22 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Mar 24
DEF 14A
Definitive proxy
26 Mar 24
10-K
2023 FY
Annual report
22 Mar 24
DFAN14A
Additional proxy materials by non-management
19 Mar 24
PRE 14A
Preliminary proxy
15 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6 Mar 24
8-K
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
22 Feb 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6 Sep 23
Transcripts
SLRX
Earnings call transcript
2022 Q2
8 Aug 22
SLRX
Earnings call transcript
2022 Q1
13 May 22
SLRX
Earnings call transcript
2021 Q4
11 Mar 22
SLRX
Earnings call transcript
2021 Q3
7 Nov 21
SLRX
Earnings call transcript
2021 Q3
4 Nov 21
SLRX
Earnings call transcript
2021 Q2
8 Aug 21
SLRX
Earnings call transcript
2021 Q2
5 Aug 21
SLRX
Earnings call transcript
2021 Q1
12 May 21
SLRX
Earnings call transcript
2020 Q4
18 Mar 21
SLRX
Earnings call transcript
2020 Q3
11 Nov 20
Latest ownership filings
4
David J. Arthur
12 Apr 24
4
Mark J Rosenblum
22 Feb 24
4
William K. McVicar
22 Feb 24
4
Bruce J Jr. McCreedy
22 Feb 24
4
Jonathan I Lieber
22 Feb 24
4
Paul Lammers
22 Feb 24
4
Tess Burleson
22 Feb 24
4
ARNOLD C HANISH
22 Feb 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13D
Lee Elvin Sanghwan
27 Oct 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 7.58 mm | 7.58 mm | 7.58 mm | 7.58 mm | 7.58 mm | 7.58 mm |
Cash burn (monthly) | 1.32 mm | 769.97 k | 844.06 k | 1.53 mm | 1.25 mm | 1.34 mm |
Cash used (since last report) | 8.99 mm | 5.24 mm | 5.75 mm | 10.44 mm | 8.51 mm | 9.11 mm |
Cash remaining | -1.41 mm | 2.34 mm | 1.83 mm | -2.86 mm | -929.74 k | -1.53 mm |
Runway (months of cash) | -1.1 | 3.0 | 2.2 | -1.9 | -0.7 | -1.1 |
Institutional ownership, Q2 2023
94.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 16 |
Opened positions | 4 |
Closed positions | 2 |
Increased positions | 2 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 292.02 mm |
Total shares | 4.08 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Lincoln Park Capital Fund | 2.97 mm | $802.00 k |
CVI Investments | 804.35 k | $732.00 k |
Armistice Capital | 109.64 k | $163.36 mm |
Lind Global Fund II | 89.09 k | $0.00 |
Horizon Kinetics Asset Management | 32.40 k | $48.28 mm |
Renaissance Technologies | 20.54 k | $31.00 k |
Geode Capital Management | 16.52 k | $24.62 mm |
Vanguard | 14.96 k | $22.30 mm |
Susquehanna International | 10.46 k | $15.59 mm |
Tower Research Capital | 8.22 k | $12.25 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Apr 24 | Arthur David J. | Stock Option Common Stock | Grant | Acquire A | No | No | 0.51 | 20,500 | 10.46 k | 20,500 |
20 Feb 24 | Rosenblum Mark J | Stock Option Common Stock | Grant | Acquire A | No | No | 0.5711 | 22,500 | 12.85 k | 22,500 |
20 Feb 24 | McVicar William K. | Stock Option Common Stock | Grant | Acquire A | No | No | 0.5711 | 20,500 | 11.71 k | 20,500 |
20 Feb 24 | McCreedy Bruce J Jr. | Stock Option Common Stock | Grant | Acquire A | No | No | 0.5711 | 20,500 | 11.71 k | 20,500 |
20 Feb 24 | Lieber Jonathan I | Stock Option Common Stock | Grant | Acquire A | No | No | 0.5711 | 20,500 | 11.71 k | 20,500 |
News
12 Health Care Stocks Moving In Wednesday's Intraday Session
27 Mar 24
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
25 Mar 24
12 Health Care Stocks Moving In Monday's Pre-Market Session
25 Mar 24
Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket
25 Mar 24
Dada Nexus, Salarius Pharmaceuticals And 3 Stocks To Watch Heading Into Monday
25 Mar 24